News

• M30 Apoptosense® ELISA in detecting NAFLD

• – What is NAFLD and what is the role of K18 in NAFLD?
• – How can the M30® aid in staging NAFLD and detecting NASH?
• – How can M30® incorporating biomarker scores help in detecting fibrotic NASH?

Click here to access the full brochure!

• Keratin 18 in NAFLD clinical trials

• – What is NAFLD and what is the role of K18 in NAFLD?
• – What are the main challenges in todays NAFLD clinical trials?
• – How can the VLVbio K18 assays aid in pre-screening subjects
  for inclusion in the trials?
• – How can the VLVbio K18 assays be used as an end-point in the trials?

Click here to access the full broschure!

• M30 Apoptosense® ELISA in paediatric NAFLD

• – What is paediatric NAFLD and what is the role of K18 in NAFLD?
• – How can M30® aid in detecting NASH in children?
• – How can M30® be incorporated into screening of patients with
  childhood obesity to identify metabolic complications?

Click here to access the full broschure!

• The full VLVbio K18 assays including the PEVIVA product line!

• – M30 Apoptosense® ELISA
• – M65® ELISA
• – M65 EpiDeath® ELISA
• – M30 CytoDeath™ ELISA
• – M65 EpiRat™ ELISA

Click here to access the full Product Line!

MEDICA 2021 – Live in Düsseldorf!

Meet us at the MEDICA fair in Düsseldorf this November!

MEDICA is the world’s leading medical trade fair with thousands of visitors every year and we are happy to know that this year will be a live in-person fair again! We are very much looking forward to finally meeting our friends, colleagues, collaborators and all other stakeholders in the field. If you are also attending the fair, do not hesitate to reach out to us to book in a meeting. Looking forward to seeing you all there!

Click here to find our contact information!

VLVbio are proud to be a part of the 2020 Your Liver Campaign by Health Awareness UK!

Non-alcoholic fatty liver disease (NAFLD) is associated with risks of cancer, transplant and even death, yet few at risk of developing the disease are aware of the implications.

“The prevalence of NAFLD has increased significantly in industrialized countries in recent decades and is now at a high level globally. This is related to the so-called Western lifestyle; fast food, lifestyle changes and reduced physical activity” says Prof. Dr. Ali Canbay.

To help fight this silent disease, using non invasive biomarkers is of utmost importance. Dr Slavica Brnjic, CEO at VLVbio says:

“One of the pressing needs in the field is to implement non-invasive and low-cost techniques for diagnosing and staging NASH. Our work at VLVbio is to spread information on the disease as well as increase the acceptance and adoption of non-invasive diagnostic techniques.”

To give rise to awareness on this global disease, we recently worked with Health Awareness on the 2020 Your Liver campaign. A printed publication was enclosed within every copy of the Guardian newspaper and the content is available online, click the link below! The campaign featured exclusive content from key thought leaders and industry voices about the various liver conditions, treatment options and the importance of early diagnosis.

Click here to read the whole piece